AstraZeneca Posts Q2 Beat, Reaffirms 2026 Outlook
AstraZeneca beat second-quarter profit expectations and reaffirmed its 2026 outlook despite concerns about future growth after a trial setback, as investors await further details on its earnings trajectory. Analysts are mixed but broadly positive, with several buy ratings and a focus on the upcoming Q2 results and oncology-driven revenue, amid a broader market backdrop of cautious trading ahead of earnings.
